NCT06598787View on ClinicalTrials.gov

A Study of BL-B01D1 in Patients With Recurrent Glioblastoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 17, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Recurrent Glioblastoma
Interventions
DRUG

BL-B01D1 for Injection

Administration by intravenous infusion for a cycle of 3 weeks.

Trial Locations (1)

Unknown

RECRUITING

Beijing Tiantan Hospital, Capital Medical University, Beijing

All Listed Sponsors
collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY